David Dillon

Has grant

Assistant Professor

university of california davis medical center
Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

David Dillon is an Assistant Professor at the University of California Davis Medical Center in the United States. His research primarily focuses on emergency medicine, specifically in the areas of cardiac arrest management, resuscitation, and the associated systemic disparities in healthcare. Recent publications include studies on prehospital care guidelines, randomized trials in cardiac arrest, and the impact of naloxone on out-of-hospital cardiac arrests.

Recent Grants

Grant: Close

Improving the Identification of Opioid-Associated Out-of-Hospital Cardiac Arrest

Open Date: 2023-09-01

Close Date: 2025-08-31

Articles (14)

Objective Despite frequent treatment of alcohol withdrawal syndrome (AWS) in the emergency department (ED), evidence for phenobarbital (PB) as an ED alternative therapy is mixed. We conducted a systematic review and meta‐analysis comparing safety and efficacy of PB to benzodiazepines (BZDs) for treatment of AWS in the ED. Methods We searched articles and references published in English in PubMed, Web of Science, and Embase from inception through May 2022. We included randomized trials and cohort studies comparing treatment with PB to BZD controls and excluded studies focused on non‐AWS conditions. Review was conducted by two blinded investigators and a third author; eight of 59 (13.6%) abstracts met inclusion criteria for review and meta‐analysis using a random‐effects model. Treatment superiority was evaluated through utilization, pharmacologic, and clinical outcomes. Primary outcomes for meta‐analysis were the proportion of patients (1) admitted to the intensive care unit (ICU), (2) admitted to the hospital, (3) readmitted to the ED after discharge, and (4) who experienced adverse events. Results Eight studies (two randomized controlled trials, six retrospective cohorts) comprised data from 1507 patients in 2012 treatment encounters for AWS. All studies were included in meta‐analysis for adverse events, seven for hospital admission, five for ICU admission, and three for readmission to the ED after discharge. Overall methodological quality was low‐moderate, risk of bias moderate‐high, and statistical heterogeneity moderate. Pooled relative risk of ICU admission for those treated with PB versus BZD was 0.92 (95% confidence interval [CI] 0.54–1.55). Risk for admission to the hospital was 0.98 (95% CI 0.89–1.07) and for any adverse event was 1.1 (95% CI 0.78–1.57); heterogeneity prevented meta‐analysis for ED readmission. Conclusions The current literature base does not show that treatment with PB significantly reduces ICU admissions, hospital admissions, ED readmissions, or adverse events in ED patients with AWS compared with BZDs alone.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Collaborators (6)

Sean Callahan

Associate Professor

University of Utah

UNITED STATES
View details

Ralph Wang

Associate Clinical Professor

University of California, San Francisco

UNITED STATES
View details

Kirby Mayer

Assistant Professor

University of Kentucky

UNITED STATES
View details

Shijing Jia

University of Michigan

UNITED STATES
View details

Charles E. Murphy

-

UNITED STATES
View details

Vidya Eswaran

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.